{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:15:37Z","timestamp":1720534537885},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":4876,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1093\/annonc\/mdl253","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T17:45:25Z","timestamp":1159897525000},"page":"x155-x159","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S10","title":["Current treatment strategies in follicular lymphomas"],"prefix":"10.1016","volume":"17","author":[{"given":"W.","family":"Hiddemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl253_bb0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl253_bb0020","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0025","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0040","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"Van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0045","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0050","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0055","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0060","first-page":"354a","article-title":"Comparison of CHVP + Interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden Follicular Lymphoma: Results of the randomized GELF94 trial (G.E.L.A. Study Group)","volume":"102","author":"Sebban","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0065","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","article-title":"Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma","volume":"32","author":"Howe","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdl253_bb0075","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0080","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0085","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdl253_bb0095","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0105","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with Rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00d74 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0110","first-page":"102","article-title":"Scheduled Rituximab maintenance therapy versus Rituximab retreatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma (NHL) responding to single-agent Rituximab: a randomized trial of the Minnie Pearl Cancer Research Network","volume":"69a","author":"Hainswoth","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0115","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular Non-Hodgkin\u2019s lymphoma treated with Rituximab plus CHOP chemotherapy: 9 year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0120","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0125","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0135","doi-asserted-by":"crossref","first-page":"584a","DOI":"10.1182\/blood.V104.11.584.584","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0140","doi-asserted-by":"crossref","first-page":"160a","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to aIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0145","first-page":"556","article-title":"Results of E 1496: A phase III trial of CVP with or without maintenance Rituximab in advanced indolent lymphoma (NHL)","volume":"23","author":"Hochster","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0150","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/jco.2005.23.16_suppl.566","volume":"23","author":"Hiddemann","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0155","first-page":"169a","article-title":"Chimeric anti-CD 20 monoclonal antibody (Rituximab, Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: A phase III randomized intergroup clinical trial","volume":"104","author":"Van Oers","year":"2005","journal-title":"Proc Am Soc Hematol"},{"key":"10.1093\/annonc\/mdl253_bb0160","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0165","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I Tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl253_bb0175","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0180","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicularnon- Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0185","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood.V90.8.3173","article-title":"Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin\u2019s lymphoma","volume":"90","author":"Gascoyne","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0190","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2000.18.9.1812","article-title":"Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin\u2019s lymphoma","volume":"18","author":"Waters","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0195","doi-asserted-by":"crossref","first-page":"392a","DOI":"10.1182\/blood.V104.11.1398.1398","article-title":"In vivo downregulation of bcl-2 by G3139 (G) enhances Rituximab \u00ae anti-tumor activity: Effect of sequential versus concurrent G3139 administration on survival in a lymphoma-bearing SCID mouse model","volume":"104","author":"Ramanarayanan","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdl253_bb0205","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0210","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1386.1386","article-title":"Phase II clinical study of Bortezomib (VELCADE\u00ae) in patients (pts) with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL) and Hodgkin\u2019s disease (HD)","volume":"104","author":"Strauss","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0215","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0220","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0225","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-04-0447","article-title":"PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism","volume":"64","author":"Adams","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl253_bb0230","doi-asserted-by":"crossref","first-page":"394a","DOI":"10.1182\/blood.V104.11.1403.1403","article-title":"Phase I study of Talabostat and Rituximab in patients with indolent non-Hodgkin\u2019s lymphoma with primary resistance to or progression following Rituximab","volume":"104","author":"Al-Katib","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl253_bb0235","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl253_bb0240","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nature Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963680X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963680X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/suppl_10\/x155\/403416\/mdl253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T03:25:29Z","timestamp":1589426729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341963680X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":47,"alternative-id":["S092375341963680X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl253","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}